Affiliations: [a] Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark
| [b] Department of Clinical Research, University of Southern Denmark, Odense, Denmark
| [c] Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
Correspondence:
[*]
Correspondence to: Poul F. Høilund-Carlsen, MD, DMSc, Prof (Hon), Professor of Clinical Physiology, Department of Nuclear Medicine, Odense University Hospital, 5000 Odense C, Denmark. Tel.: +45 25215445; E-mail: pfhc@rsyd.dk; ORCID ID 0000-0001-7420-2367
Abstract: According to the FDA, aducanumab (Aduhelm), the recently approved anti-Alzheimer drug, reduces the level of cerebral amyloid plaques—a hallmark finding in patients with Alzheimer’s disease—and this will result in a reduction in clinical decline. The authors of this article are not convinced that amyloid deposits are a hallmark of Alzheimer’s disease and are of the opinion that the apparent reduction in amyloid accumulation following aducanumab treatment is likely instead a result of continued and advanced cerebral cell death and, thus, not a sign of improvement but of an even more advanced disease.
